DRKS00000781招募中不适用
on-interventional study about safety and efficacy of chemo-therapy with Paclitaxel Stragen(R) / Eurotaxel(R) (new name of the prescription) as mono or combined therapy for routine treatment of ovarial or breast cancer with special consideration of age and BMI starting position. - ET-001
apharm GmbH0 个研究点目标入组 1,500 人开始时间: 2011年4月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- Female
入选标准
- •Histologically secured ovarial or breast cancer.
- •Signed patient informed consent form.
排除标准
- •Other malign diseases in the past 5 years.
- •Lack of compliance.
研究者
相似试验
招募中
不适用
on-interventional study on the safety and efficacy of an Abraxane(R) mono therapy for the therapy of patients with metasasized breast cancer with special consideration of the toxicity profilesC50Malignant neoplasm of breastDRKS00003203OnkoDataMed GmbH !450
尚未招募
3 期
A randomized control trial to study the antibody response and side effects after the booster dose of COVID-19 vaccineCTRI/2022/01/039677Institute of Liver and Biliary Sciences
已完成
不适用
A clinical study investigating the safety, efficacy and performance of the URECA CTO device.Chronic Total Occlusion(s)10003216ArteriosclerosisNL-OMON55292reca B.V.40
已完成
3 期
BS054 Clinical StudyJPRN-jRCT2092220032Boston Scientific Japan K.K.20
已完成
不适用
Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma.CD20-positive B-cell lymphomaJPRN-UMIN000003641Japanese Red Cross Medical Center15